Small molecules which reverse Doxorubicin treatment
Canned Analysis
FAIR Metrics
0 evaluations
General Information
AccessionDCA00011875
TitleSmall molecules which reverse Doxorubicin treatment
DescriptionThe L1000 database was queried in order to identify small molecule perturbations which reverse the gene expression signature induced by Doxorubicin treatment in the Eµ-myc transgenic lymphoma cells deficient in Suv39h1 cell type.
Analysis URLhttp://amp.pharm.mssm.edu/L1000CDS2/#/result/58d1edb3e467bea600fb99b4
Upload DateSeptember 20, 2017
Uploadermaayanlab
Metadata
Analysis Curatortimkenny92
CREEDS IDdrug:2486
Cell TypeEµ-myc transgenic lymphoma cells deficient in Suv39h1
Drug NameDoxorubicin
DrugBank IDDB00997
Organismmouse
PubChem CID31703
SMILES IDCC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O
L1000CDS2 parameters
Directionreverse
Characteristic Direction parameters
Control SamplesGSM1083870, GSM1083872, GSM1083874, GSM1083876, GSM1083878
Perturbed SamplesGSM1083871, GSM1083873, GSM1083875, GSM1083877, GSM1083879
Tools used in the analysis
Dataset Accession
L1000CDS2
Published August 2016
An ultra-fast LINCS L1000 Characteristic Direction signature search engine
7756
Characteristic Direction
Published March 2014
A geometrical multivariate approach to identify differentially expressed genes
26829
Datasets used in the analysis
Keyword
Tool Name
GSE44355
Gene Expression Omnibus
Adriamycin in vitro effect on E-myc transgenic lymphoma cells deficient in Suv39h1
7
FAIR Evaluation
Sorry, you must be signed in to evaluate this object.